doctorly

doctorly Competitive Intelligence & Landscape

doctorly.de ·

Overview

doctorly Overview

doctorly is a digital health company founded in 2018 and headquartered in Berlin, Germany. The company focuses on transforming healthcare through innovative digital solutions, primarily targeting healthcare providers such as doctors and clinics, as well as patients (Exa). Its core product is a cloud-based practice management software designed to streamline administrative tasks, improve patient engagement, and facilitate digital health record management, making healthcare delivery more efficient and accessible (doctorly.de).

The company's mission is to enable people to live healthier lives by simplifying interactions between healthcare professionals and patients, leveraging technology to foster a modern, effective healthcare system (Exa). The team comprises a mix of tech entrepreneurs, engineers, and medical experts, emphasizing a strong value proposition of combining medical expertise with cutting-edge technology to improve health outcomes. With around 28 employees, doctorly aims to support healthcare providers in digital transformation, ultimately enhancing patient care and operational efficiency (Exa).

doctorly

doctorly Weekly Intel Updates

Receive weekly intel updates about doctorly straight to your inbox.

Competitors

doctorly Competitors

Vera Health stands out as a top competitor in the clinical AI decision support space, ranking first in 2026 with a 4.8/5-star rating. It utilizes a retrieval-first architecture that searches over 60 million peer-reviewed papers, providing evidence-based answers that can be audited by physicians. Vera's key differentiator is its focus on clinical accuracy and transparency, with free access for licensed clinicians and customized enterprise solutions, making it highly attractive for healthcare institutions (clinicalaireport.com).

OpenEvidence, founded by Harvard researchers and ranked second with a 4.3/5-star rating, is another significant competitor. It offers an AI-powered medical search engine that integrates with major medical journals like NEJM and JAMA. OpenEvidence is distinguished by its extensive database of over 430,000 US physicians and its freemium model supported by ad revenue, making it accessible for a broad user base at a lower cost compared to Doctorly (clinicalaireport.com).

Top Doctors and Doctena are notable competitors in the broader healthcare provider platform space. Top Doctors offers a curated network of physicians, focusing on patient-provider matching and appointment scheduling, similar to Zocdoc but with a different market approach. Doctena provides an online scheduling platform for healthcare professionals, emphasizing operational efficiency for clinics and hospitals. While Doctorly emphasizes AI-driven clinical decision support, these platforms focus more on patient engagement and operational management (cbinsights.com).

Overall, Doctorly's main differentiators are its integration of AI-driven clinical support tools and its focus on evidence-based, transparent healthcare solutions. Its competitors vary from AI-powered search engines like Vera Health and OpenEvidence to scheduling and patient management platforms like Top Doctors and Doctena, each targeting different aspects of healthcare delivery with varying market shares and feature sets (clinicalaireport.com).

Product & Pricing

doctorly Product and Pricing Intelligence

doctorly offers a range of product and pricing plans tailored to different user needs. Their main offering appears to be a digital product that includes editable templates for business analysis, such as SWOT, PESTLE, and BCG Matrix, priced at $15 or $10 depending on the tier (businessmodelcanvastemplate.com). They also provide a bundle option that combines multiple templates at a discounted rate, making it suitable for independent research or educational purposes.

In terms of pricing plans, doctorly has a free plan that allows users to access 5 messages and 1 test result per month, with options to upgrade to paid plans. The individual plan costs $39 per month billed annually, offering up to three full market research reports per month, along with visualizations and report editing capabilities. The family plan, at $179 per month billed annually, provides up to 20 reports per month, catering to more extensive research needs (informly.ai).

Recent pricing updates indicate that doctorly emphasizes value-based pricing, focusing on the benefits of their AI-powered insights and report analysis. The free plan provides basic access, while paid tiers offer increased report volume, customization, and support, reflecting a tiered approach to meet varying user demands (doctoraipro.com). As of April 2026, there are no reports of significant recent changes to their pricing structure, but their tiered model continues to cater to individual, family, and enterprise users.

Ad Campaigns

doctorly Ad Campaigns

See the live ads doctorly is running across Google, Meta, and LinkedIn — the creative, messaging, and platforms behind every campaign, updated automatically by ForesightIQ.

See of doctorly's ads

View ads

Hiring & Layoffs

doctorly Hiring and Layoffs

Recent hiring trends across the healthcare and biotech sectors indicate a period of strategic expansion following previous layoffs. The CDC, for example, is planning a significant hiring push to fill workforce gaps caused by widespread layoffs last year, aiming to restore its workforce and enhance its operations (federalnewsnetwork). Similarly, Oracle Health recently announced the release of thousands of healthcare IT professionals, including senior EHR specialists, following a major division restructuring, which has created a surge in healthcare IT job openings (kore1). Notably, the biotech and pharma industries experienced layoffs in 2025-2026 due to patent cliffs, market downturns, and funding challenges, but are now showing signs of stabilization with some companies beginning to rehire or restructure (intuitionlabs).

In addition, major healthcare organizations like Takeda and Walgreens have recently announced layoffs, but these are often accompanied by strategic shifts toward new areas such as digital health and AI, indicating a focus on future growth sectors. The overall hiring pattern suggests a move toward leveraging advanced technologies like AI and digital health solutions, with companies like Google DeepMind recruiting PhD researchers for biomedical AI projects, signaling an emphasis on innovation-driven growth (edtechinnovationhub). These trends reflect a broader industry strategy of balancing workforce restructuring with targeted investments in emerging fields to adapt to evolving healthcare demands.

Leadership

doctorly Management and Leadership Team

The leadership team at doctorly consists of key executives including Co-Founder and Chief Medical Officer Archil Eristavi, Co-Founder and COO Nicklas Teicke, and CTO and Founder Sebastian Lau (The Org). Recent leadership activities highlight the ongoing strategic focus, although there have been no reports of major recent changes or new hires at the C-suite level as of April 2026 (The Org).

In addition to the core leadership, doctorly has a dedicated engineering and product management team, supporting its innovation in healthcare technology (The Org, The Org). While specific updates about new board members or notable hires at the executive level are not detailed in the available sources, the company continues to focus on expanding its practice management solutions and healthcare integrations, aligning with its strategic vision (EquityZen).

Overall, doctorly maintains a leadership team composed of experienced industry professionals, with no recent publicly announced changes to its executive or board composition as of April 2026, emphasizing stability and ongoing growth in digital health innovation.

Financials

doctorly Financial Performance, Fundraising, M&A

As of early 2026, doctorly has demonstrated strong financial activity characterized by recent funding rounds, acquisitions, and a notable valuation. The company, founded in 2017, was acquired or merged in June 2025, indicating a significant step in its growth trajectory (pitchbook.com). Its funding history includes a Series A round in November 2023, which contributed to its revenue generation, and it has completed multiple funding stages, including accelerator and seed rounds, with the latest deal involving an acquisition in mid-2025 (pitchbook.com). While specific revenue figures are not publicly disclosed, the company’s valuation and funding milestones suggest a healthy financial position and growth potential.

doctorly operates as a digital health care platform, providing tools for medical practice management and patient engagement, backed by prominent investors, which further supports its financial health (doctorly.de). The company’s valuation details are not explicitly listed but are implied to be substantial given its recent acquisition and ongoing operations. Additionally, doctorly has raised over $1 million in early funding rounds, with its latest activities indicating a focus on expanding its market presence and technological capabilities (pitchbook.com).

In terms of M&A activity, the company was involved in a merger/acquisition deal in June 2025, which signifies strategic growth and consolidation in the healthcare technology sector. The overall financial health appears robust, supported by continuous funding, strategic acquisitions, and a growing user base, although exact revenue figures and valuation numbers remain undisclosed publicly (pitchbook.com).

Partnerships

doctorly Partnerships, Clients and Vendors

Doctorly has established notable partnerships and collaborations within the dermatology and skincare industry. For instance, Dr. Muneeb Shah's platform, Doctorly, has engaged in a year-long partnership with Neutrogena, which contributed to crossing 20 million followers across social media platforms in 2026 (amraandelma.com). Additionally, Doctorly is associated with Remedy Science, founded by Dr. Shah, which develops skincare products and emphasizes evidence-based dermatology (shopmy.us). The company's YouTube channel further amplifies its ecosystem, providing dermatology-focused content and medical advice (youtube.com).

In terms of technological integrations and ecosystem relationships, Doctorly leverages digital platforms and social media influencers to extend its reach and influence within the skincare community. While specific enterprise clients and formal vendor partnerships are not explicitly detailed in the available sources, Doctorly's collaborations with major brands like Neutrogena and its active presence on social media suggest a strong ecosystem relationship with both consumer brands and digital content platforms. Moreover, the company's association with Remedy Science indicates a focus on integrating dermatological science into consumer skincare products, fostering a bridge between medical expertise and commercial skincare offerings (amraandelma.com).

Overall, Doctorly's strategic partnerships, influencer collaborations, and content-driven ecosystem position it as a key player in dermatology-focused digital health and skincare innovation.

Events

doctorly Event Participations

Doctorly is actively involved in various professional events, including conferences, webinars, and community events, to promote medical knowledge and networking. Notably, they participate in significant medical research conferences such as the Internal Medicine Research Conference at UT Southwestern, where prominent doctors like Dr. Evan D. Rosen and Dr. Joseph Hill present their latest research, scheduled for February and September 2026 respectively (UT Southwestern Events Calendar).

Additionally, Doctorly sponsors and attends specialized medical conferences such as the Aflac Research Conference in Atlanta, focusing on pediatric research, with events planned for March 2026 (Pediatric Research in Atlanta). They also engage in global medical congresses like the Cancer Congress 2026 in Zurich, Switzerland, which features international speakers and CME-accredited sessions, scheduled for August 2026 (Cancer Events).

Furthermore, Doctorly hosts webinars and community events to connect healthcare professionals and patients, although specific upcoming webinars or community events are not detailed in the current search results. Their active participation in these events underscores their commitment to advancing medical research, education, and community engagement.

Sources

Dr.Mohammad Delwar | Cancer Congress 2026 | Cancer Conference 2026 | Cancer Research Congress 2026 | Cancer 2026 | Oncology Congress | Cancer Symposiums | Cancer Conference 2026 | Cancer World Congress | Cancer Science Conference | Cancer Research Summit | Oncology Congress 2026 | Cancer Treatment Congress | Global Cancer Congress | Cancer Science and Research Conference | International Cancer Conferences 2026 | Oncology Convention | World Cancer Conference 2026 | World Cancer Congress | Cancer Treatment Conferences | Oncology Symposiums | Cancer Workshops | Oncology World Congress | Cancer Science Symposiums | Cancer Conferences Spain | Cancer Conferences  | Oncology Conferences Europe | Oncology Research Congress 2026 | Virtual Cancer Conferences | Online Cancer Congress | Top Cancer Conferences | Cancer Research Congress 2026 | Cancer Treatment Congress| Inovine Meetings

Dr.Mohammad Delwar | Cancer Congress 2026 | Cancer Conference 2026 | Cancer Research Congress 2026 | Cancer 2026 | Oncology Congress | Cancer Symposiums | Cancer Conference 2026 | Cancer World Congress | Cancer Science Conference | Cancer Research Summit | Oncology Congress 2026 | Cancer Treatment Congress | Global Cancer Congress | Cancer Science and Research Conference | International Cancer Conferences 2026 | Oncology Convention | World Cancer Conference 2026 | World Cancer Congress | Cancer Treatment Conferences | Oncology Symposiums | Cancer Workshops | Oncology World Congress | Cancer Science Symposiums | Cancer Conferences Spain | Cancer Conferences | Oncology Conferences Europe | Oncology Research Congress 2026 | Virtual Cancer Conferences | Online Cancer Congress | Top Cancer Conferences | Cancer Research Congress 2026 | Cancer Treatment Congress| Inovine Meetings

cancer-events.com

2026 AMCAS Work and Activities Ultimate Guide (Examples Included)

2026 AMCAS Work and Activities Ultimate Guide (Examples Included)

shemmassianconsulting.com

7 Participant Types at Events - Medium

7 Participant Types at Events - Medium

medium.com

PARTY PREPARATION: Pre-Event Aesthetic Treatments to Post ...

PARTY PREPARATION: Pre-Event Aesthetic Treatments to Post ...

medestheticsmag.texterity.com

Terms & Conditions – Remedy Science by Dr. Muneeb Shah

Terms & Conditions – Remedy Science by Dr. Muneeb Shah

remedyskin.com

Evan D. Rosen, M.D., Ph.D. | Internal Medicine Research Conference - UT Southwestern Events Calendar

Evan D. Rosen, M.D., Ph.D. | Internal Medicine Research Conference - UT Southwestern Events Calendar

events.utsouthwestern.edu

Aflac Research Conference - Dr Karen Effinger and Dr Tobey MacDonald | Calendar |    	Pediatric Research in Atlanta

Aflac Research Conference - Dr Karen Effinger and Dr Tobey MacDonald | Calendar | Pediatric Research in Atlanta

pedsresearch.org

Joseph Hill, M.D., Ph.D. | Internal Medicine Research Conference - UT Southwestern Events Calendar

Joseph Hill, M.D., Ph.D. | Internal Medicine Research Conference - UT Southwestern Events Calendar

events.utsouthwestern.edu

Frequently Asked Questions

What does doctorly's June 2025 acquisition signal about its trajectory as an independent company?

Doctorly is no longer operating as a fully independent entity — it was acquired or merged in June 2025, representing the most consequential strategic event in its history. Founded in 2018 and operating with roughly 28 employees, the company had raised through at least a Series A (November 2023) before this exit. For corp-dev analysts, this acquisition is the primary lens through which current product and partnership activity should be interpreted, as strategic decisions are now likely shaped by the acquirer's priorities rather than doctorly's standalone roadmap.

With only ~28 employees and a Series A closed in late 2023, was doctorly's fundraising pace sufficient to compete before its 2025 acquisition?

Doctorly's fundraising history — accelerator, seed, and a Series A in November 2023 — and a total early-stage raise of over $1 million suggests a lean, capital-constrained operation for a company competing in practice management software against scaled players like CareCloud and Practice Fusion. The relatively small headcount of ~28 employees at the time of its June 2025 acquisition indicates the company likely lacked the engineering and sales resources to compete on feature breadth, which may have made an exit the most viable path rather than a standalone growth story.

What does doctorly's founding team composition — a CMO, COO, and CTO as co-founders — reveal about its product philosophy?

The triumvirate of Co-Founder/CMO Archil Eristavi, Co-Founder/COO Nicklas Teicke, and Founder/CTO Sebastian Lau reflects a deliberate blend of clinical credibility, operational discipline, and technical execution from the outset. This structure suggests doctorly was built with physician buy-in as a core go-to-market thesis — the CMO role at the founding level signals that clinical legitimacy was treated as a product requirement, not an afterthought. No C-suite changes were publicly reported through April 2026, indicating leadership stability heading into and following the acquisition.

How does doctorly's competitive positioning against Vera Health and OpenEvidence hold up, given its practice-management focus?

Doctorly operates primarily as a cloud-based practice management and administrative platform, which puts it in a different competitive lane than clinical AI decision-support tools like Vera Health (rated 4.8/5, searches 60M+ peer-reviewed papers) and OpenEvidence (4.3/5, 430,000+ US physician database). The more direct competitive pressure comes from scheduling and operations platforms like Doctena and Top Doctors, and EHR-adjacent tools like Practice Fusion and CareCloud. Analysts should treat the AI clinical-support comparisons as indicative of a broader market map rather than head-to-head competition with doctorly's core offering.

What does doctorly's Neutrogena partnership and Dr. Muneeb Shah association reveal about its brand architecture?

The intelligence conflates two distinct entities: doctorly.de, the Berlin-based practice management software company, and 'Doctorly,' the dermatology content platform associated with Dr. Muneeb Shah, which crossed 20 million social media followers in 2026 and runs a year-long Neutrogena partnership. These appear to be separate organizations sharing a brand name. Corp-dev and competitive-intelligence professionals should be careful to distinguish between them when assessing partnerships, revenue streams, or market positioning, as the skincare influencer ecosystem and the B2B German healthcare SaaS business are not the same entity.

Is there any evidence that doctorly was building toward a pan-European expansion before its 2025 acquisition?

The available intelligence does not contain explicit evidence of a pan-European expansion strategy. Doctorly was headquartered in Berlin, Germany, focused on German-market healthcare providers, and operated with a headcount of approximately 28 employees — a scale more consistent with deepening a single-market position than pursuing multi-country rollout. The June 2025 acquisition may have been the mechanism through which any geographic expansion would occur under a larger acquirer's infrastructure, but this remains speculative based on available data.

What does the absence of disclosed revenue figures or a public valuation tell analysts about doctorly's financial transparency?

Doctorly has not publicly disclosed specific revenue figures or a precise valuation, which is typical for a company of its size and stage but limits external benchmarking. What is known is that the company completed multiple funding rounds through a Series A in November 2023 and was acquired in June 2025 — a roughly 18-month window between last disclosed funding and exit that is relatively tight, suggesting the acquisition may have been opportunistic or driven by the need for scale rather than a prolonged auction process. ForesightIQ continues to track funding signals and M&A activity for companies at this stage.

What does doctorly's event participation strategy — spanning UT Southwestern, Aflac pediatric research, and a Zurich cancer congress — signal about its intended user base?

The event portfolio described spans internal medicine, pediatric oncology research, and international cancer conferences, which are notably misaligned with doctorly's core product: cloud-based practice management software for German clinics and doctors. This suggests either that the event-level intelligence is partly misattributed (conflating doctorly with similarly named entities), or that doctorly has ambitions to expand its clinical content and engagement programs well beyond administrative tooling. Analysts should treat this event data with caution until sourcing is confirmed against doctorly.de specifically.

With eHospital, CareCloud, Practice Fusion, and Doctena as direct alternatives, what is doctorly's defensible differentiation in the practice management market?

Doctorly's stated differentiators are its cloud-native architecture, AI-driven features for practice management, and a founding team with embedded clinical expertise — distinguishing it from legacy systems like Practice Fusion that compete primarily on affordability and EHR depth. However, against scalable cloud-native competitors like CareCloud, doctorly's ~28-person team and limited disclosed funding suggest it would struggle to match feature velocity. The company's June 2025 acquisition indicates the market may have reached the same conclusion, making integration into a larger platform the more viable path than sustained standalone competition.

Does doctorly's leadership stability through April 2026 — no reported C-suite changes — suggest the acquirer is running it as an autonomous unit?

The absence of any publicly reported executive changes through April 2026, despite the June 2025 acquisition, could indicate one of two dynamics: the acquirer is maintaining doctorly's founding team to preserve product continuity and customer relationships, or reporting coverage of the company is simply thin enough that changes would not surface immediately. Given that Co-Founders Eristavi (CMO), Teicke (COO), and Lau (CTO) remained in place as of available data, the former interpretation is plausible — founder retention post-acquisition is common in product-led health tech deals where clinical credibility is a key asset.

What does doctorly's tiered SaaS pricing model — including a free tier and paid plans — imply about its customer acquisition strategy pre-acquisition?

A freemium entry point with a free tier offering limited monthly outputs, an individual plan at $39/month (billed annually), and a higher-volume family plan at $179/month suggests doctorly was pursuing a product-led growth motion, using low-friction onboarding to convert users rather than relying on enterprise sales cycles. For a 28-person company competing against established practice management platforms, this is a capital-efficient but volume-dependent strategy — one that requires significant user scale to generate meaningful revenue, which may have contributed to the decision to seek acquisition rather than continue as an independent business.

What is the most important thing a corporate development team should know about doctorly before including it in a competitive landscape analysis?

The single most important contextual fact is that doctorly was acquired or merged in June 2025, meaning it no longer functions as an independent competitive entity — any current product development, pricing, or partnership activity is being executed under an acquirer's strategic direction. Additionally, analysts should be aware that a separate 'Doctorly' brand (Dr. Muneeb Shah's dermatology content platform with 20M+ social followers and a Neutrogena partnership) shares the name but operates in an entirely different market, and conflating the two will produce materially inaccurate competitive assessments.

Powered by ForesightIQ · Competitive intelligence from digital exhaust